Woburn, Massachusetts - August 4, 2010- CRi will announce and demonstrate a new Maestro™ system for in vivo kinetic imaging at a Workshop in Kyoto at the World Molecular Imaging Congress. Leading researchers will discuss how they use their CRi Maestro™ In-Vivo Imaging Systems to investigate target identification, tumor tracking, antibody labeling and kinetic modeling. Discussions will also include helpful tips and tricks and updates regarding CRi’s latest system developments, including the availability of the new Maestro system with included DyCE™ (Dynamic Contrast Enhancement) technology that generates time-based images and movies of fluorescent reagents and labeled antibodies, providing quantitative data on the temporal biodistribution of fluorescent markers at much earlier time points than is possible using conventional imaging methods, and enabling better discrimination between bound and unbound antibodies.

Featured speakers at the workshop include:

- Hisataka Kobayashi, Staff Scientist, NIH Molecular Imaging Program

- Yasuteru Urano, University of Tokyo

- Zhuang Liu, Soochow University

- James R. Mansfield, Director, Multispectral Imaging Systems, CRi

Workshop details:

- Tuesday, September 7, 2010 (Day before the WMIC conference begins)

- 2:00 pm to 5:30 pm

- Room K, International Conference Center, Kyoto, Japan

Refreshments and hors d’oeuvres will be provided and seating is limited.

Sign Up Now.

Burlington, Mass - July19th, 2010- Aspen Technology, Inc. (NASDAQ: AZPN), a leading provider of software and services to the process industries, today announced that GlaxoSmithKline, AstraZeneca and other pharmaceutical industry leaders are reducing their research and development time and costs using newly patented technology that is part of AspenTech’saspenONE Process Development for Pharmaceuticals software.

• The solubility modeling technology – developed in collaboration with pharmaceutical companies – provides “Quality by Design” (QbD) capabilities that help manufacturers comply with the latest industry regulatory initiatives.
• Using the aspenONE software, GSK is able to throroughly understand the solubility properties of new chemical entities (NCE) to assess more quickly risks and improve confidence during the development of new pharmaceuticals. As part of the aspenONE® for Pharmaceuticals suite, drug companies can also ensure a highly repeatable manufacturing process.
• This simulation modeling technology optimizes crystallization design workflow by allowing pharmaceutical companies to:
  • Save time and money. By quickly evaluating the solubility properties of a NCE, laboratories can focus precious experimentation efforts in areas that have a high likelihood of success based on the simulation results. Drug solubility is a critical factor in determining efficient manufacturing processes for a candidate drug.
  • Conduct clinical trials earlier. Begin process development activities sooner using the predictive modeling capabilities of the software to quickly design optimized manufacturing and purification processes.
  • Reduce cost of goods and supply disruptions. Enable informed design of the final Active Pharmaceutical Ingredient (API) manufacturing processes so they are optimized to produce less waste and higher yield.
• AspenTech received the patent for creating a nonrandom two-liquid segment activity coefficient (NRTL-SAC) model that provides a simple yet scientific basis to predict drug solubility. This is the latest of dozens of patents issued to AspenTech for innovative solutions in process optimization.

Supporting Quotes:
Stephen Carino, Investigator – Solid Form Sciences Group, GlaxoSmithKline
“Screening for crystalline forms is an essential component in pharmaceutical drug development. In our high-throughput screening workflow, we have utilized NRTL-SAC in Aspen Properties to predict the equilibrium solubility of the drug in single- and multi-component solvent systems. The predicted solubility values are used in selecting an appropriate set of solvent systems that are explicitly unique for each of the crystallization modes. This rational solvent selection coupled with the systematic screening approach has allowed us to assess risk around solid forms and improve our confidence in the robustness of the API processes.”

Jamie Hintlian, Vice President of Pharmaceuticals, Aspen Technology, Inc.
“Solubility is essential in evaluating drug candidacy and manufacturability. Without predictive tools, many organizations are forced to fly blind when it comes to this mission-critical information. Solubility modeling and prediction adds value by enabling greater efficiencies, better decision making, faster process development, and better process performance. For the pharmaceutical industry leaders involved in its development, and other potential users, this is a powerful screening protocol for the drug development process.”

Supporting Resources:

• aspenONE for Pharmaceuticals
• aspenONE Customer Testimonials
• USPTO – NRTL-SAC Patent Approval

About AspenTech
AspenTech is a leading supplier of software that optimizes process manufacturing – for energy, chemicals, pharmaceuticals, engineering and construction, and other industries that manufacture and produce products from a chemical process. With integrated aspenONE solutions, process manufacturers can implement best practices for optimizing their engineering, manufacturing and supply chain operations. As a result, AspenTech customers are better able to increase capacity, improve margins, reduce costs and become more energy efficient. To see how the world’s leading process manufacturers rely on AspenTech to achieve their operational excellence goals, visit www.aspentech.com.

Burlington, Mass - July 13, 2010 -Aspen Technology, Inc. (NASDAQ: AZPN), a leading provider of software and services to the process industries, today announced the availability of the 7.2 release of aspenONE software. Building on innovations delivered in aspenONE V7 and best practice input from users, the 7.2 release makes optimizing engineering, manufacturing and supply chain processes faster and easier. Examples include:

• Engineering – addressing the global increase in multibillion dollar “megaprojects,” aspenONE® Engineering software includes new economic evaluation functionality that allows large owner-operator and engineering companies to slash the amount of time it takes to produce accurate project estimates by as much as 75%. In addition, integrated economic evaluation is now up to four times faster in Aspen HYSYS® and Aspen Plus® software.
• Manufacturing – in the face of dynamic market conditions, aspenONE Advanced Process Control allows process manufacturers to sustain performance improvement benefits from advanced process control by reducing the time and effort required to maintain control applications at peak performance.
• Supply Chain – as government standards for gasoline blending specifications become more stringent, aspenONE Planning & Scheduling allows refineries to model true physical constraints for better blend optimization. This is a critical step in improving margins and specification quality.
• Infrastructure – the new Aspen Reporting Framework™ provides operational intelligence for refineries that enables faster, more profitable decision-making.

The new features are the latest in a series of innovations delivered by aspenONE V7, which sets the standard for best practices in process optimization. For information on these and many other new features and enhancements in the 7.2 release of aspenONE, visit http://www.aspentech.com/v7/v72_enhancements.cfm.

Supporting Quote
Manolis Kotzabasakis, Senior Vice President, Sales & Strategy, AspenTech
“Since its initial release in September 2008, over 1,000 AspenTech customers have deployed aspenONE V7 to help improve profitability and achieve operational excellence goals. The 7.2 release incorporates hundreds of best practice ideas from our customer base. Now, it’s easier than ever for process industry companies to optimize engineering, manufacturing and supply chain processes for greater profitability.”

Supporting Resources

• About the 7.2 release of aspenONE V7

About AspenTech
AspenTech is a leading supplier of software that optimizes process manufacturing – including energy, chemicals, pharmaceuticals, engineering & construction, power & utilities and other industries that manufacture and produce products from a chemical process. With integrated aspenONE solutions, process manufacturers can implement best practices for optimizing their engineering, manufacturing and supply chain operations. As a result, AspenTech customers are better able to increase capacity, improve margins, reduce costs and become more energy efficient. To see how the world’s leading process manufacturers rely on AspenTech to achieve their operational excellence goals, visit www.aspentech.com.

Innov-X Systems C.E.O. Don Sackett commented:  “We are extremely honored to be part of the Olympus organization, which is so well respected throughout the world.  Innov-X has newly introduced an X-ray fluorescence product platform that is both high performance and rugged and is a great fit with the nondestructive testing and remote visual inspection technologies of Olympus.  I look forward to the synergies and opportunities to extend our technological leadership and quality created by the joining of these two companies.”

For more information on Innov-X Systems, please visit www.innovx.com.

Woburn, Massachusetts June 22, 2010 -

Cambridge Research & Instrumentation, Inc. (CRi), a leader in pre-clinical and molecular imaging, today announced the appointment of Darren Lee as the company’s vice president of marketing. He will be responsible for leading all strategic marketing activities for the company’s products and sales across the United States and worldwide.

“CRi’s technology is positioned to lead the emerging field of tissue-based multiplexed analysis from basic research through diagnostics,” said Lee. “I’m excited about the opportunity to help drive growth in these key segments, further enabling our customers to more rapidly identify and validate biomarkers of disease, leading to new therapeutics and companion diagnostics.”

Lee comes to CRi with more than 20 years of experience in marketing management, business development and engineering in the life sciences and clinical diagnostics industries.

“Darren’s extensive experience and proven leadership in the field of biotechnology will be a tremendous asset,” said George Abe, president and chief executive officer of CRi. “We are excited to add him to our management team and believe his expertise will contribute greatly to the continued development of the company.”

Lee has held senior-level management positions at Primera Biosystems, a molecular diagnostics company, and Decision Biomarkers, a life-science systems developer. He has also served in senior management positions at PerkinElmer and Packard Bioscience. He has a B.S. in Biomedical Engineering Technology from Temple University and an M.S. in Technology Management from Pepperdine University.

About CRi, Inc.

Cambridge Research & Instrumentation, Inc. (CRi) develops and markets optical imaging systems to advance biomedical research and molecular-based drug and diagnostic development. CRi’s patented systems enable researchers and clinicians to quantitate multiple disease and drug response markers in intact tissue samples, at a cellular level or in living small animals. CRi’s products integrate a unique multispectral imaging technology with proprietary image analysis algorithms to achieve unparalleled accuracy and sensitivity, rapidly and cost-effectively. CRi’s award-winning systems include Nuance™ for multispectral imaging on brightfield and fluorescence microscopes; inForm™ automated image analysis software; Vectra™ for high-throughput slide imaging and analysis; and Maestro™ for in-vivo optical imaging. Learn more at www.cri-inc.com.

For more information, contact:

Cambridge Research & Instrumentation, Inc. (CRi)

Cathy Boutin

781-935-9099

Marketing Manager

cboutin@cri-inc.com

Commonwealth Creative Associates

Jamie Bull

508-620-0791

Digital Media Strategist

jamieb@commcreative.com

Commonwealth Creative Associates

Donna Phelps

508-620-0791

Senior Account Executive

donnap@commcreative.com

Newton, Mass. June 16, 2010 — Curaspan Health Group, the industry leader in building secure electronic patient-transition networks for hospitals, post-acute providers and suppliers, has helped Riverside Health System (RHS) dramatically increase referrals within its network. In one year, in-network patient placements jumped from 30% to 60%.

Serving the communities of Southeastern Virginia with an integrated delivery network of hospitals, surgery centers, retirement communities, assisted-living facilities, long-term care facilities, physician practice locations and other services, RHS deployed the Curaspan eDischarge^TM software-as-a-service (SaaS) application as its platform for enhancing communication, operations and care network-wide.

“We look across the system, at all the facilities, and we see the whole pie – not just one slice,” said Dawn Kowalski, operations manager for Riverside Health System. “We could not do this without Curaspan.” The RHS collaboration with Curaspan is detailed in a new case study, Riverside Health System Knocks Down IT Silos, Builds New Model of Care Facilitation.

“It’s the patient that counts, not a building,” added Melody Livengood, RN, MSN, director of care facilitation at RHS. “We’re looking at what’s best for the patient.”

Built with clinical expertise from case managers, discharge planners and social workers, Curaspan SaaS applications empower users with actionable data to help streamline the patient-transition process, improve the quality of care, and by extension, the bottom line.

“We’re very pleased that our partnership with Riverside is contributing to demonstrable benefits with quantifiable results for the system and its patients,” said Thomas R. Ferry, president and CEO of Curaspan.

Curaspan works with many of the nation’s top hospitals and post-acute care providers including Johns Hopkins Health System, New York Presbyterian, St. Thomas Health Services (part of Ascension Health), Vanguard Health Systems, Amedisys Home Health Services, American Medical Response, Gentiva Health Services, Golden LivingCenters, Kindred Healthcare, Life Care Centers of America and Sunbridge Health, among many others.

About Curaspan Health Group
Curaspan Health Group builds secure electronic patient-transition networks for hospitals, post-acute providers and suppliers to optimize patient care. Curaspan software-as-a-service (SaaS) applications empower users with real-time, predictive decision-making data that enables all participants to continuously monitor care, improve communication and ensure compliance. This informatics exchange is integrated with the proprietary Curaspan Provider Data Bank, the industry’s most comprehensive and up-to-date system of actionable patient-transition intelligence, and is complemented by the clinical process expertise of credentialed advisors. The Health Care Advisory Board and KLAS repeatedly have recognized Curaspan for its industry-leading software. Curaspan is headquartered in Newton, Mass. For more information please visit Curaspan.com.

Media Contact:
Sarah Mees
KMC Partners Public Relations
978-208-1499
Sarah@KMCPartners.com

Download PDF

Burlington, Mass.  May 6th 2010 - Aspen Technology, Inc. (NASDAQ: AZPN), a leading provider of software and services to the process industries, today announced financial results for its third quarter of fiscal 2010, ended March 31, 2010.

Mark Fusco, Chief Executive Officer of AspenTech, said, “The positive momentum of AspenTech’s business continued during the third quarter. Product related bookings of approximately $94 million were consistent with the level of our seasonally stronger second quarter due primarily to customer interest in moving to our new aspenONE licensing model, in addition to expanded usage across our customer base. On a fiscal year-to-date basis, the company’s license bookings are up approximately 10% compared to the comparable period in fiscal 2009, which we believe is a strong performance considering fiscal 2010 is the first year of our new aspenONE licensing model.”

Fusco added, “We are pleased with the company’s cash flow in the third quarter. We generated $19.4 million in cash flows from operations, which enabled the company to grow its cash balance by nearly $10 million at the same time secured borrowings were reduced by $9.1 million. We are at the early stages of ramping the company’s subscription cash flow model and we are encouraged by our progress and long-term outlook.”

AspenTech’s total revenue of $45.6 million decreased from $71.3 million in the third quarter of the prior year, due primarily to the ratable revenue recognition associated with the company’s new aspenONE licensing model.

• Subscription revenue includes all revenue associated with the company’s new aspenONE licensing model. Subscription revenue was approximately $4.0 million in the third quarter of fiscal 2010, an increase from $1.2 million last quarter. No subscription revenue was recorded in the year ago period as the company’s new aspenONE licensing model was launched during the first quarter of fiscal 2010. Subscription revenue is recognized over the course of the multi-year agreement, and recognition begins when the first payment is due, which is typically 30 days after the contract is signed.
• Software revenue includes all non-subscription-based license revenue, including term-based contracts for point products as well as perpetual licenses. Software revenue was $14.7 million in the third quarter of fiscal 2010, compared to $41.1 million in the year ago period. In fiscal year 2010, software revenue related to term contracts is recognized over the contract term, generally as payments become due. In prior fiscal year periods, the company recognized term license revenue predominantly on an up-front basis, and the majority of license bookings were recognized as license revenue in the same period.
• Services & other revenue, which includes professional services, maintenance and other revenue, was $26.9 million in the third quarter of fiscal 2010, a decrease compared to $30.2 million in the year ago period.

For the quarter ended March 31, 2010, AspenTech reported a loss from operations of $19.6 million due primarily to the ratable revenue recognition associated with the company’s new aspenONE licensing model. For the quarter ended March 31, 2009, the company reported income from operations of $4.5 million. Net loss was $21.8 million for the third quarter of fiscal 2010, leading to net loss per basic and diluted share of $0.24 compared to net income per diluted share of $0.09 in the same period last year.

AspenTech had a cash balance of $119.1 million at March 31, 2010, an increase of $9.6 million from the end of the prior quarter. The company did not sell any installments receivable to raise cash during the third quarter of fiscal 2010 and it continued to reduce its secured borrowings balance, which was $87.4 million at the end of the quarter, down $9.1 million compared to $96.5 million at the end of the second quarter of fiscal 2010.

Other Third Quarter Business Metrics

• The company closed 21 product related bookings of over $1 million during the third quarter, and 39 product related bookings between $250,000 and $1 million.
• Average deal size for product related bookings over $100,000 was $807,000 in the third quarter.

Conference Call and Webcast

AspenTech will host a conference call and webcast today, May 6, at 5:00 p.m. (Eastern Time), to discuss the company’s financial results for the third quarter of fiscal 2010 as well as the company’s business outlook. The live dial-in number is (877) 245-0126, conference ID code 70000573. Interested parties may also listen to a live webcast of the call by logging on to the Investor Relations section of AspenTech’s website, http://www.aspentech.com/corporate/investor.cfm, and clicking on the “webcast” link. A replay of the call will be archived on AspenTech’s website and will also be available via telephone at (800) 642-1687 or (706) 645-9291, conference ID code 70000573 through May 13, 2010.

About AspenTech

AspenTech is a leading supplier of software that optimizes process manufacturing – for energy, chemicals, pharmaceuticals, engineering and construction, and other industries that manufacture and produce products from a chemical process. With integrated aspenONE solutions, process manufacturers can implement best practices for optimizing their engineering, manufacturing and supply chain operations. As a result, AspenTech customers are better able to increase capacity, improve margins, reduce costs and become more energy efficient. To see how the world’s leading process manufacturers rely on AspenTech to achieve their operational excellence goals, visit www.aspentech.com.

© 2010 Aspen Technology, Inc., AspenTech, aspenONE and the Aspen leaf logo are trademarks of Aspen Technology, Inc. All rights reserved. All other trademarks are property of their respective owners.

Forward-Looking Statements

The second and third paragraphs of this press release may contain forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements relating to the anticipated benefits of AspenTech’s new subscription-based licensing model. Actual results may vary significantly from AspenTech’s expectations based on a number of risks and uncertainties, including, without limitation: customers’ failure to adopt the new AspenONE licensing model at the rate expected by AspenTech or at all; AspenTech’s failure to realize the anticipated financial and operational benefits of the new AspenONE licensing model; unforeseen difficulties or uncertainties in the application of accounting standards; weaknesses in our internal controls, including our controls over the recognition of license revenue; and other risk factors described from time to time in AspenTech’s periodic reports filed with the Securities and Exchange Commission.

AspenTech cannot guarantee any future results, levels of activity, performance, or achievements. AspenTech expressly disclaims any current intention to update forward-looking statements after the date of this press release.

Full financial tables available via the PDF link at the top of this page

NEWTON, Mass. — May 18, 2010 — Curaspan Health Group, the industry leader in building secure electronic patient-transition networks for hospitals, post-acute providers and suppliers, today announced that president and CEO Thomas R. Ferry has joined the board of directors of the Epilepsy Therapy Project. Founded in 2002, the Epilepsy Therapy Project brings together scientific, business and community leaders dedicated to advancing new therapies for epilepsy.

Epilepsy is a neurological disorder involving abnormal electrical activity in the brain. An estimated three million people nationwide have been diagnosed with epilepsy, including one of Ferry’s children. When poorly controlled or uncontrolled, this condition can lead to significant impairment and mortality. Approximately 200,000 new cases of epilepsy will be diagnosed in the United States this year, affecting as many people as breast cancer.

“The combination of Tom’s deep interest in our work and his business acumen makes him an ideal addition to our board,” says Warren Lammert, chairman and co-founder of the Epilepsy Therapy Project.

The Epilepsy Therapy Project provides clinical and critical product development funding, as well as scientific and business direction to promising new therapies and invests in programs and platforms that can take time and costs out of new therapy development.

Ferry adds, “I can’t overemphasize the importance of the work done by this organization. The Epilepsy Therapy Project provides resources to help bring new drugs to market and gives tremendous hope to those affected by epilepsy that there will be better treatments soon, and ultimately a cure.”

Ferry founded Curaspan 11 years ago, after his family faced the daunting challenge of finding the best nursing home for a beloved relative being discharged from the hospital. It was a frustrating process that sparked his idea of using technology to help streamline patient transitions. Today, Curaspan HIPAA-compliant software is repeatedly recognized for excellence by the Health Care Advisory Board and KLAS, the health-care IT research firm.

Built with clinical expertise from case managers, discharge planners and social workers, Curaspan software-as-a-service (SaaS) applications empower users with actionable data to help streamline the patient-transition process, improve the quality of care, and by extension, the bottom line. With no capital investment required, the average hospital can be up and running in six to eight weeks, with less than three hours of staff training. Last year, the Curaspan eDischarge^TM application helped facilitate the smooth transition of almost 600,000 patients.

Curaspan works with many of the nation’s top hospitals and post-acute care providers including Johns Hopkins Health System, New York Presbyterian, St. Thomas Health Services (part of Ascension Health), Vanguard Health Systems, Amedisys Home Health Services, American Medical Response, Gentiva Health Services, Golden LivingCenters, Kindred Healthcare, Life Care Centers of America and Sunbridge Health, among many others.

About Curaspan Health Group
Curaspan Health Group builds secure electronic patient-transition networks for hospitals, post-acute providers and suppliers to optimize patient care. Curaspan software-as-a-service (SaaS) applications empower users with real-time, predictive decision-making data that enables all participants to continuously monitor care, improve communication and ensure compliance. This informatics exchange is integrated with the proprietary Curaspan Provider Data Bank, the industry’s most comprehensive and up-to-date system of actionable patient-transition intelligence, and is complemented by the clinical process expertise of credentialed advisors. The Health Care Advisory Board and KLAS repeatedly have recognized Curaspan for its industry-leading software. Curaspan is headquartered in Newton, Mass. For more information, please visit Curaspan.com.

About the Epilepsy Therapy Project
The Epilepsy Therapy Project is a non-profit organization whose mission is to accelerate new therapies for people living with epilepsy and seizures. Founded in 2002 by a group of parents, distinguished physicians and researchers, the Epilepsy Therapy Project supports the commercialization of new therapies through direct grants and investments in promising academic and commercial projects. Learn more at Epilepsy.com.

Media Contact:
Sarah Mees
KMC Partners Public Relations
978-208-1499
Sarah@KMCPartners.com

Susan Pietropaolo
BCC Partners for the Epilepsy Therapy Project
201-923-2049
SPietropaolo@BCCPartners.com

Burlington, Mass. - May 13th, 2010 - Aspen Technology, Inc. (NASDAQ: AZPN), a leading provider of software and services to the process industries, today announced that over 160 success stories were presented by AspenTech customers at the 2010 aspenONE Global Conference, held from May 3-6 in Boston. Over 500 customers from more than 200 process manufacturing companies in 43 countries shared best practices for using process optimization software to capture opportunity in today’s changing global economy.

• The aspenONE Global Conference is the only industry conference exclusively focused on optimizing process manufacturing from design, through manufacturing and supply chain operations.
• AspenTech President & CEO Mark Fusco opened the event introducing the 2010 conference theme: “Capturing Opportunity.” Following a keynote presentation by AspenTech Senior Vice President Manolis Kotzabasakis, leading process industry senior executives discussed how optimizing the entire process manufacturing value chain can deliver superior operational and financial results. Customer keynote speakers included:
  • Maggi Walker, VP of Engineering Solutions, Dow Chemical Company
  • Ed Daniels, EVP, Shell Global Solutions Downstream
  • Maurice Tayeh, SVP and CIO, Technip
• Following the opening session, the keynote speakers engaged in an interactive panel discussion moderated by FIATECH’s Executive Director, Dr. Ric Jackson.
• During the conference, over 160 papers were presented across Engineering, Manufacturing and Supply Chain tracks that addressed the most pressing issues process industry companies face today including energy management, GHG reduction, integrated supply chain planning, manufacturing operations, megaprojects, alternative fuels, and achieving operational excellence.
• The conference also included the first ever AspenTech University Forum, with professors from MIT, University of Pennsylvania, Lehigh University, Virginia Polytechnic Institute and State University, University of Washington and others participating. These academic leaders discussed how to enhance university curricula to train the next generation of engineering professionals by further incorporating engineering software and best practices for knowledge transfer.

Supporting Resources:

• aspenONE 2010 Global Conference web page
• aspenONE 2010 Global Conference Twitter feed
• aspenONE 2010 Global Conference customer video on Facebook

About AspenTech
AspenTech is a leading supplier of software that optimizes process manufacturing – for energy, chemicals, pharmaceuticals, engineering and construction, and other industries that manufacture and produce products from a chemical process. With integrated aspenONE solutions, process manufacturers can implement best practices for optimizing their engineering, manufacturing and supply chain operations. As a result, AspenTech customers are better able to increase capacity, improve margins, reduce costs and become more energy efficient. To see how the world’s leading process manufacturers rely on AspenTech to achieve their operational excellence goals, visit www.aspentech.com.